Contact
searchSearch
HMP Global
Login

Substance Use Disorder

a man surrounded by alcohol and other substances on a table
News
Reduced Stimulant Use Outcomes May Reveal Treatment Effects Missed by Abstinence Measures
06/18/2026
Maria Mantas
Evaluating reduced stimulant use rather than complete abstinence outcomes in patients with stimulant use disorder could provide additional insight into treatment efficacy.
Evaluating reduced stimulant use rather than complete abstinence outcomes in patients with stimulant use disorder could provide additional insight into treatment efficacy.
Evaluating reduced stimulant use...
06/18/2026
Psych Congress Network
A lab tech handles psilocybin research
FDA Update
FDA Vouchers Fast-Track Psychedelic Drugs for Depression and PTSD – Psych Congress Responds With Expert Briefing
04/29/2026
Brionna Mendoza
Following an April 18 executive order, the US Food and Drug Administration (FDA) announced new regulatory actions to accelerate the development of psychedelic-assisted therapy for mental health conditions.
Following an April 18 executive order, the US Food and Drug Administration (FDA) announced new regulatory actions to accelerate the development of psychedelic-assisted therapy for mental health conditions.
Following an April 18 executive...
04/29/2026
Psych Congress Network
A man sits by water with a journal open on his lap for writing
Conference Coverage
Written Exposure Therapy Boosts Recovery Capital in SUD and PTSD
04/27/2026
Brionna Mendoza
New randomized controlled trial data presented at ASAM 2026 highlighted the benefits of integrating Written Exposure Therapy (WET) into residential substance use disorder (SUD) treatment.
New randomized controlled trial data presented at ASAM 2026 highlighted the benefits of integrating Written Exposure Therapy (WET) into residential substance use disorder (SUD) treatment.
New randomized controlled trial...
04/27/2026
Psych Congress Network
NYSAM 2026 Meeting Logo
Conference Coverage
NYSAM 2026 Spotlights Harm Reduction, Psychiatric Care in SUD Treatment
03/17/2026
Brionna Mendoza
At the 2026 New York Society of Addiction Medicine (NYSAM) Annual Conference in New York, clinicians and policymakers focused on integrating evolving policy with patient-centered addiction care.
At the 2026 New York Society of Addiction Medicine (NYSAM) Annual Conference in New York, clinicians and policymakers focused on integrating evolving policy with patient-centered addiction care.
At the 2026 New York Society of...
03/17/2026
Psych Congress Network
Evguenia Makovkina, MD
Conference Coverage
Education Intervention Boosts Psychiatrists’ Knowledge and Attitudes on mOUD
03/07/2026
Evguenia Makovkina, MD
Evguenia Makovkina, MD, discusses key findings from her pilot study examining psychiatrists’ baseline knowledge, attitudes, and prescribing practices related to medications for opioid use disorder (mOUD).
Evguenia Makovkina, MD, discusses key findings from her pilot study examining psychiatrists’ baseline knowledge, attitudes, and prescribing practices related to medications for opioid use disorder (mOUD).
Evguenia Makovkina, MD,...
03/07/2026
Psych Congress Network
a man smoking and drinking
News
Psychological Interventions Offer Minimal Impact in Schizophrenia With SUD
02/05/2026
Maria Mantas
A large systematic review and meta-analysis found psychological and psychosocial interventions had minimal impact in individuals with co-occurring schizophrenia and substance use disorder (SUD).
A large systematic review and meta-analysis found psychological and psychosocial interventions had minimal impact in individuals with co-occurring schizophrenia and substance use disorder (SUD).
A large systematic review and...
02/05/2026
Psych Congress Network
a person breaks a cigarette in half
News
GLP-1 Agonists Show Promise in Treating Alcohol and Substance Use Disorders
11/13/2025
Brionna Mendoza
A review published in the Journal of the Endocrine Society highlights the emerging potential of GLP-1 receptor agonists (GLP-1RAs) as pharmacotherapies for alcohol and substance use disorders (ASUDs).
A review published in the Journal of the Endocrine Society highlights the emerging potential of GLP-1 receptor agonists (GLP-1RAs) as pharmacotherapies for alcohol and substance use disorders (ASUDs).
A review published in the...
11/13/2025
Psych Congress Network
woman surrounded by spilled pills
News
Heart Rate Variability Biofeedback May Reduce Craving and Substance Use During SUD Recovery
10/09/2025
Maria Mantas
Second-generation heart rate variability biofeedback (HRVB) reduced negative affect, craving, and substance use in individuals in early recovery from severe substance use disorder (SUD), according to phase 2 trial results.
Second-generation heart rate variability biofeedback (HRVB) reduced negative affect, craving, and substance use in individuals in early recovery from severe substance use disorder (SUD), according to phase 2 trial results.
Second-generation heart rate...
10/09/2025
Psych Congress Network
tipped over pill bottle with white pills spilling out
News
Fewer Than Half of Medicaid Managed Care Plans Cover All Medications For AUD
04/22/2025
Maria Mantas
Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.
Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.
Fewer than half of all Medicaid...
04/22/2025
Psych Congress Network
Woman sitting at bar holding a drink.
News
Semaglutide Reduces Cravings in Adults with Alcohol Use Disorder
03/13/2025
Jolynn Tumolo
Nine weeks of low-dose semaglutide decreased the amount of alcohol consumed, relative to placebo, in a laboratory test involving adults with AUD who were not seeking treatment, study finds.
Nine weeks of low-dose semaglutide decreased the amount of alcohol consumed, relative to placebo, in a laboratory test involving adults with AUD who were not seeking treatment, study finds.
Nine weeks of low-dose...
03/13/2025
Psych Congress Network
a cartoon illustration of a man sitting on the floor with this hand on his head, looking distressed.
News
More Than a Fifth of Overdose Decedents Had Non–Substance Mental Health Disorder
09/23/2024
Jolynn Tumolo
In 2022, 1 in 5 overdose deaths in the United States involved people with mental health disorders (MHD) unrelated to substance use, according to a study published in Morbidity and Mortality Weekly Report.
In 2022, 1 in 5 overdose deaths in the United States involved people with mental health disorders (MHD) unrelated to substance use, according to a study published in Morbidity and Mortality Weekly Report.
In 2022, 1 in 5 overdose deaths...
09/23/2024
Psych Congress Network

More News & Updates

a man surrounded by alcohol and other substances on a table
News
Reduced Stimulant Use Outcomes May Reveal Treatment Effects Missed by Abstinence Measures
06/18/2026
Maria Mantas
Evaluating reduced stimulant use rather than complete abstinence outcomes in patients with stimulant use disorder could provide additional insight into treatment efficacy.
Evaluating reduced stimulant use rather than complete abstinence outcomes in patients with stimulant use disorder could provide additional insight into treatment efficacy.
Evaluating reduced stimulant use...
06/18/2026
Psych Congress Network
a man smoking and drinking
News
Psychological Interventions Offer Minimal Impact in Schizophrenia With SUD
02/05/2026
Maria Mantas
A large systematic review and meta-analysis found psychological and psychosocial interventions had minimal impact in individuals with co-occurring schizophrenia and substance use disorder (SUD).
A large systematic review and meta-analysis found psychological and psychosocial interventions had minimal impact in individuals with co-occurring schizophrenia and substance use disorder (SUD).
A large systematic review and...
02/05/2026
Psych Congress Network
a person breaks a cigarette in half
News
GLP-1 Agonists Show Promise in Treating Alcohol and Substance Use Disorders
11/13/2025
Brionna Mendoza
A review published in the Journal of the Endocrine Society highlights the emerging potential of GLP-1 receptor agonists (GLP-1RAs) as pharmacotherapies for alcohol and substance use disorders (ASUDs).
A review published in the Journal of the Endocrine Society highlights the emerging potential of GLP-1 receptor agonists (GLP-1RAs) as pharmacotherapies for alcohol and substance use disorders (ASUDs).
A review published in the...
11/13/2025
Psych Congress Network
woman surrounded by spilled pills
News
Heart Rate Variability Biofeedback May Reduce Craving and Substance Use During SUD Recovery
10/09/2025
Maria Mantas
Second-generation heart rate variability biofeedback (HRVB) reduced negative affect, craving, and substance use in individuals in early recovery from severe substance use disorder (SUD), according to phase 2 trial results.
Second-generation heart rate variability biofeedback (HRVB) reduced negative affect, craving, and substance use in individuals in early recovery from severe substance use disorder (SUD), according to phase 2 trial results.
Second-generation heart rate...
10/09/2025
Psych Congress Network
tipped over pill bottle with white pills spilling out
News
Fewer Than Half of Medicaid Managed Care Plans Cover All Medications For AUD
04/22/2025
Maria Mantas
Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.
Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.
Fewer than half of all Medicaid...
04/22/2025
Psych Congress Network
Woman sitting at bar holding a drink.
News
Semaglutide Reduces Cravings in Adults with Alcohol Use Disorder
03/13/2025
Jolynn Tumolo
Nine weeks of low-dose semaglutide decreased the amount of alcohol consumed, relative to placebo, in a laboratory test involving adults with AUD who were not seeking treatment, study finds.
Nine weeks of low-dose semaglutide decreased the amount of alcohol consumed, relative to placebo, in a laboratory test involving adults with AUD who were not seeking treatment, study finds.
Nine weeks of low-dose...
03/13/2025
Psych Congress Network
a cartoon illustration of a man sitting on the floor with this hand on his head, looking distressed.
News
More Than a Fifth of Overdose Decedents Had Non–Substance Mental Health Disorder
09/23/2024
Jolynn Tumolo
In 2022, 1 in 5 overdose deaths in the United States involved people with mental health disorders (MHD) unrelated to substance use, according to a study published in Morbidity and Mortality Weekly Report.
In 2022, 1 in 5 overdose deaths in the United States involved people with mental health disorders (MHD) unrelated to substance use, according to a study published in Morbidity and Mortality Weekly Report.
In 2022, 1 in 5 overdose deaths...
09/23/2024
Psych Congress Network
Mark Garofoli
Q&As
A Closer Look at the Updated CDC Opioid Guideline
09/08/2024
Mark Garofoli, PharmD, MBA
Dr Garofoli discusses the key changes in the CDC's 2022 Opioid Guideline Update and their impact on clinical practice, highlights the expanded scope of the guidelines to all outpatient settings, the nuanced approach to pain management, and...
Dr Garofoli discusses the key changes in the CDC's 2022 Opioid Guideline Update and their impact on clinical practice, highlights the expanded scope of the guidelines to all outpatient settings, the nuanced approach to pain management, and...
Dr Garofoli discusses the key...
09/08/2024
Psych Congress Network
Ken J. Martz, PsyD, MBA.
Q&As
Tapping Into Neuroplasticity to Power Addiction Recovery
09/06/2024
Ken J. Martz, PsyD, MBA
Kenneth J. Martz, PsyD, MBA, discusses how neuroplasticity can amplify traditional recovery techniques.
Kenneth J. Martz, PsyD, MBA, discusses how neuroplasticity can amplify traditional recovery techniques.
Kenneth J. Martz, PsyD, MBA,...
09/06/2024
Psych Congress Network
A person sits holding a pill in one hand and a glass of water in the other
News
Most US Residents Unaware PCPs Can Prescribe Medication for Opioid Use Disorder
08/19/2024
Jolynn Tumolo
Three-quarters of US residents in a national survey did not know primary care physicians (PCPs) could prescribe medications for people with opioid use disorder (OUD) or believed incorrectly that they could not, according to a study findings...
Three-quarters of US residents in a national survey did not know primary care physicians (PCPs) could prescribe medications for people with opioid use disorder (OUD) or believed incorrectly that they could not, according to a study findings...
Three-quarters of US residents...
08/19/2024
Psych Congress Network
Rakesh Jain, MD, MPH
Rapid Reaction
Rapid Reactions: Eli Lilly Acquisition Highlights Momentum in Psychedelics for Mental Health
07/16/2026
Rakesh Jain, MD, MPH, RD; Maria Mantas
Rakesh Jain, MD, MPH, responds to news that Eli Lilly and Company plans to acquire AtaiBeckley Inc, expanding its presence in the emerging field of psychedelic-based treatments for depression and other psychiatric conditions.
Rakesh Jain, MD, MPH, responds to news that Eli Lilly and Company plans to acquire AtaiBeckley Inc, expanding its presence in the emerging field of psychedelic-based treatments for depression and other psychiatric conditions.
Rakesh Jain, MD, MPH, responds...
07/16/2026
Psych Congress Network
Rakesh Jain, MD, MPH
Videos
The Sleep Disorder Missteps Clinicians Can Learn From
07/16/2026
Rakesh Jain, MD, MPH, RD
Rakesh Jain, MD, MPH, Co-Chair, Psych Congress discusses why sleep complaints in psychiatric practice warrant direct evaluation rather than dismissal as secondary symptoms.
Rakesh Jain, MD, MPH, Co-Chair, Psych Congress discusses why sleep complaints in psychiatric practice warrant direct evaluation rather than dismissal as secondary symptoms.
Rakesh Jain, MD, MPH, Co-Chair,...
07/16/2026
Psych Congress Network
a stethoscope, pills, and brain
Research Summary
Biobehavioral Markers May Improve Antidepressant Response in Major Depressive Disorder
07/16/2026
Maria Mantas
Patients with MDD and favorable biobehavioral markers for sertraline and/or bupropion experienced higher antidepressant response rates than those with negative markers for both drugs.
Patients with MDD and favorable biobehavioral markers for sertraline and/or bupropion experienced higher antidepressant response rates than those with negative markers for both drugs.
Patients with MDD and favorable...
07/16/2026
Psych Congress Network
an illustration of a man sitting on the ground holding his head with his profile and brain in the background
Research Summary
iTBS Offers Short-Term Improvement in Major Depressive Disorder
07/10/2026
Brionna Mendoza
A randomized clinical trial found that 10 once-daily sessions of iTBS produced short-term improvement compared to sham in clinician-rated depressive symptoms among adults with recurrent major depressive disorder (MDD).
A randomized clinical trial found that 10 once-daily sessions of iTBS produced short-term improvement compared to sham in clinician-rated depressive symptoms among adults with recurrent major depressive disorder (MDD).
A randomized clinical trial...
07/10/2026
Psych Congress Network
Kristian Dambrino, DNP, PMHNP-BC
Videos
Knowing When to Initiate Treatment for TD
07/07/2026
Kristian Dambrino, DNP, PMHNP, MSN
Psych Congress Elevate Co-Chair Kristian Dambrino, DNP, PMHNP-BC, discusses practical considerations for pinpointing whether and when to begin targeted treatment for tardive dyskinesia (TD).
Psych Congress Elevate Co-Chair Kristian Dambrino, DNP, PMHNP-BC, discusses practical considerations for pinpointing whether and when to begin targeted treatment for tardive dyskinesia (TD).
Psych Congress Elevate Co-Chair...
07/07/2026
Psych Congress Network
Kristian Dambrino, DNP, PMHNP-BC
Videos
Knowing When to Initiate Treatment for TD
07/07/2026
Kristian Dambrino, DNP, PMHNP, MSN
Psych Congress Elevate Co-Chair Kristian Dambrino, DNP, PMHNP-BC, discusses practical considerations for pinpointing whether and when to begin targeted treatment for tardive dyskinesia (TD).
Psych Congress Elevate Co-Chair Kristian Dambrino, DNP, PMHNP-BC, discusses practical considerations for pinpointing whether and when to begin targeted treatment for tardive dyskinesia (TD).
Psych Congress Elevate Co-Chair...
07/07/2026
Psych Congress Network
Craig Chepke and Kevin Williams
Major Depressive Disorder Insights
Anhedonia in MDD: What to Ask When Visit Time Is Short
07/07/2026
Craig Chepke, MD, DFAPA; Kevin Williams, MS, MPAS, PA-C
Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C, discuss how busy outpatient clinicians can effectively screen for anhedonia in major depressive disorder.
Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C, discuss how busy outpatient clinicians can effectively screen for anhedonia in major depressive disorder.
Craig Chepke, MD, DFAPA, and...
07/07/2026
Psych Congress Network
pills spilling out of a tipped over pill bottle
News
US Veterans Study Links SGLT2 Inhibitors to Lower Dementia Risk in Older Adults With Psychiatric Disorders
07/01/2026
Maria Mantas
Sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with a lower risk of incident all-cause dementia among older US veterans with mood and psychotic disorders. 
Sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with a lower risk of incident all-cause dementia among older US veterans with mood and psychotic disorders. 
Sodium-glucose cotransporter 2...
07/01/2026
Psych Congress Network
A patient sits across from a doctor who has a clipboard and is filling out a phone
Research Summary
Single-Dose LSD Formulation Hits Primary Endpoint in Phase 3 MDD Trial
06/29/2026
Brionna Mendoza
DT120, a proprietary formulation of lysergide (LSD) for treatment of MDD, met both primary and key secondary endpoints in the phase 3 Emerge study.
DT120, a proprietary formulation of lysergide (LSD) for treatment of MDD, met both primary and key secondary endpoints in the phase 3 Emerge study.
DT120, a proprietary formulation...
06/29/2026
Psych Congress Network
a young woman lies awake in bed
News
Adolescent Insomnia and Daytime Sleepiness Linked to Depression Risk
06/25/2026
Maria Mantas
A 3-year longitudinal study found that insomnia, excessive daytime sleepiness (EDS), and their co-occurrence were associated with increased risk of depression. 
A 3-year longitudinal study found that insomnia, excessive daytime sleepiness (EDS), and their co-occurrence were associated with increased risk of depression. 
A 3-year longitudinal study...
06/25/2026
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Insights
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use